Galapagos NV (NASDAQ:GLPG) Receives Consensus Rating of “Reduce” from Analysts

Galapagos NV (NASDAQ:GLPG) has been given an average recommendation of “Reduce” by the eight analysts that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a sell rating and four have issued a hold rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $25.33.

Several equities analysts recently issued reports on GLPG shares. TD Cowen lowered Galapagos from a “strong-buy” rating to a “strong sell” rating in a research note on Thursday, January 9th. Morgan Stanley cut Galapagos from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $31.00 to $22.00 in a research report on Friday, February 14th. Finally, Barclays reaffirmed an “underweight” rating on shares of Galapagos in a research report on Thursday, January 23rd.

Galapagos Stock Performance

NASDAQ:GLPG opened at $25.46 on Friday. The firm’s 50-day moving average is $25.07 and its 200-day moving average is $26.94. Galapagos has a 52-week low of $22.36 and a 52-week high of $32.57.

Institutional Trading of Galapagos

Several institutional investors have recently bought and sold shares of the stock. Erste Asset Management GmbH bought a new position in shares of Galapagos during the third quarter valued at $410,000. GAMMA Investing LLC lifted its holdings in Galapagos by 77.4% during the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 974 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Galapagos by 31.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company’s stock valued at $1,352,000 after purchasing an additional 11,777 shares during the last quarter. R Squared Ltd acquired a new position in Galapagos in the fourth quarter valued at about $26,000. Finally, QRG Capital Management Inc. grew its stake in Galapagos by 21.7% during the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock worth $288,000 after buying an additional 1,866 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.